VERACYTE, INC. 8-K

What Happened
Veracyte, Inc. announced preliminary, unaudited financial and operating results in a press release dated January 11, 2026 (furnished on Form 8‑K). For the fourth quarter of 2025 Veracyte expects total revenue of $138–$140 million, testing revenue of $134–$136 million, and testing volume of about 45,500 tests. For the full year ended December 31, 2025, Veracyte expects total revenue of $515–$517 million, testing revenue of $491–$493 million, testing volume of about 169,700 tests, and an adjusted EBITDA margin greater than 25%.

Key Details

• Q4 2025 estimates: Total revenue $138–$140M; testing revenue $134–$136M; testing volume ~45,500 tests.
• FY 2025 estimates: Total revenue $515–$517M; testing revenue $491–$493M; testing volume ~169,700 tests.
• FY 2025 adjusted EBITDA margin expected to be >25%.
• Results are preliminary and unaudited; audited financial statements are not yet available and figures may change. Veracyte could not provide a GAAP net income margin or a reconciliation to adjusted EBITDA without unreasonable effort due to unavailable estimates for items such as stock‑based compensation and acquisition‑related expenses.

Why It Matters
These preliminary results give investors an early view of Veracyte’s revenue, testing volumes and profitability trends heading into the audited 2025 earnings release. A >25% adjusted EBITDA margin suggests material operating profitability on a non‑GAAP basis, while testing volume figures indicate demand levels for Veracyte’s diagnostic tests. However, because the numbers are unaudited and the company has not provided a GAAP reconciliation for adjusted EBITDA, final audited results and any adjustments could materially change the reported margins and net income comparatives.